Page 2 - Cogent Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John Robinson, PhD appointed as Chief Scientific Officer to lead newly created Cogent Research team Evan Kearns, JD joined Cogent as Chief Legal Officer Ended Q1 2021 with $230.7 million in cash, sufficient to fund operations into 2024 News provided by Share this article Share this article CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (...

Cogent Biosciences Announces Creation of Cogent Research Team Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21 News provided by Share this article Share this article BOULDER, Colo. and CAMBRIDGE, Mass., April 6, 2021 /PRNew...

Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results CGT9486 clinical trial initiations on-track: Advanced Systemic Mastocytosis (1H21), Non-Advanced Systemic Mastocytosis (2H21), Gastrointestinal Stromal Tumors (GIST) (2H21) Final data from CGT9486 + sunitinib Phase 1/2 study presented at CTOS 2020 demonstrated 12 months median PFS and 20% ORR, including a complete response, in heavily pre-treated advanced GIST patients. Randomized GIST clinical trial initiation expected in 2H21 Rapidly Growing with Several Key Additions to Management Team and Board of Director...